CoChat
Sign Up
Cited by 36Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesObesity, Physical Activity, Diet

Compliance, Behavior Change, and Weight Loss With Orlistat in an Over‐the‐Counter Setting

Open access
Schwartz, Susan M., Bansal, Vidhu P., Hale, Cecilia, Rossi, Maureen, Engle, Janet P.·2008·Obesity
DOI 10.1038/oby.2007.96
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective: The study was conducted to provide information on how consumers would use orlistat 60 mg, especially in terms of product dosing, in a setting without physician supervision. Methods and Procedures: A 3‐month, open‐label, naturalistic study was conducted in an over‐the‐counter (OTC) setting in 18 pharmacies. Consumers ≥18 years were allowed to purchase orlistat packages containing a bottle of orlistat 60 mg plus educational materials, which provided lifestyle information and tools to encourage successful weight loss. Data were collected at pharmacy visits and during telephone interviews at 14, 30, 60, and 90 days after enrollment. Results: A total of 237 subjects purchased and used the product, and completed at least one interview. Most subjects followed the dosing directions and took two to three capsules per day with meals throughout the study. The majority of subjects took a daily multivitamin, as directed. Approximately, 80% of subjects used the educational materials and found them useful or very useful. Over the study duration, most subjects reported following a diet and 51% of subjects reported more frequent or longer exercise than at enrollment. Approximately, 80% of subjects indicated they were satisfied or very satisfied with the weight loss achieved; measured and self‐reported relative median weight loss was ∼5% after ≥60 days of using orlistat. Most common adverse events were gastrointestinal (GI), and majority of subjects did not interrupt or discontinue orlistat due to these GI events. Discussion: These results demonstrate that orlistat 60 mg can be used appropriately and safely and with high consumer satisfaction without physician supervision or dietary counseling. Collectively, results indicate that orlistat 60 mg is an appropriate weight loss therapy in the OTC environment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/oby.2007.96

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [2]2. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight (review). Cochrane Library 2005;1-57.
  2. [10]10. Roth H. Harriet Roth's Fat Counter, 2nd revised edn. A Signet Book, Penguin Group, New York, 2000.

Cited by

Sorted by citations

Related

Authors
Schwartz, S. M., Bansal, V. P., Hale, C., Rossi, M., & Engle, J. P.
Affiliations
  • GlaxoSmithKline (United States) (US)
  • University of Illinois Chicago (US)
Corresponding author
Schwartz, Susan M.
ORCID
Engle, Janet P.
Venue
Obesity
Publisher
Wiley
Published
2008-03
Volume
16
Issue
3
Pages
623-629
ISSN
  • 1930-7381 (ISSN-L)
  • 1930-739X
DOI
10.1038/oby.2007.96
OpenAlex
W1973147964
Cited by
36
References
9
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2021: 2 · 2020: 2 · 2018: 1 · 2017: 1 · 2016: 3 · 2014: 2 · 2013: 4 · 2012: 4
FWCI
2.80
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 1650 d)
Locations
  • Obesity (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
orlistat, weight loss, over-the-counter weight loss products, consumer compliance, dosing adherence, gastrointestinal adverse effects, customer satisfaction, diet and exercise
MeSH terms
Orlistat, Adult, Consumer Product Safety, Drug Administration Schedule, Drug Labeling, Nonprescription Drugs, Female, Humans, Health Knowledge, Attitudes, Practice, Lactones, Male, Middle Aged, Obesity, Patient Compliance, Patient Education as Topic, Time Factors, United States, Vitamins, Weight Loss, Health Behavior, Exercise, Treatment Outcome, Patient Satisfaction, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review